These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6352046)

  • 1. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
    Martucci N; Manna V; Mattesi P; Troiani G; Manzoni GC; Lanfranchi M; Bono G; Micieli G
    Cephalalgia; 1983 Aug; 3 Suppl 1():151-5. PubMed ID: 6352046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of migraine attacks through the use of dihydroergotamine.
    Neuman M; Demarez JP; Harmey JL; Le Bastard B; Cauquil J
    Int J Clin Pharmacol Res; 1986; 6(1):11-3. PubMed ID: 3514491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Migraine prevention with dihydroergotamine].
    Heuser B; Middendorf E
    Fortschr Med; 1985 Nov; 103(41):966-70. PubMed ID: 3905548
    [No Abstract]   [Full Text] [Related]  

  • 4. Timed-release dihydroergotamine in the prophylaxis of mixed headache. A study versus amitriptyline.
    Bonuso S; Di Stasio E; Barone P; Steardo L
    Cephalalgia; 1983 Aug; 3 Suppl 1():175-8. PubMed ID: 6352047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.
    D'Alessandro R; Gamberini G; Lozito A; Sacquegna T
    Cephalalgia; 1983 Aug; 3 Suppl 1():156-8. PubMed ID: 6616598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
    Aylward M; Chazot G; Maddock J; Schott B
    Presse Med; 1984 Jun; 13(26):1617-9. PubMed ID: 6234558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study.
    Bousser MG; Chick J; Fuseau E; Soisson T; Thevenet R
    Cephalalgia; 1988 Sep; 8(3):187-92. PubMed ID: 3197098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial.
    Frediani F; Grazzi L; Zanotti A; Mailland F; Zappacosta BM; Bussone G
    Cephalalgia; 1991 Jul; 11(3):117-21. PubMed ID: 1909603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
    Tulunay FC; Karan O; Aydin N; Culcuoglu A; Guvener A
    Cephalalgia; 1987 Jun; 7(2):131-3. PubMed ID: 3301001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dihydroergotamine and flunarizine in the prevention of migraine. A comparative double-blind study].
    Langohr HD; Reinecke M; Gerber WD; Mangold R
    Fortschr Med; 1988 Jan; 106(2):65-6, 69-70. PubMed ID: 3278960
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative study of indoramin versus dihydroergotamine in the preventive treatment of migraine].
    Pradalier A; Dry J; Loisy B; Meininger V; Vicaut E; Mirabaud C; Levy M
    Therapie; 1988; 43(4):293-7. PubMed ID: 3055407
    [No Abstract]   [Full Text] [Related]  

  • 13. [Double blind study of migraine therapy with etilefrine pivalate].
    Cruz A; Bühling M; Seibel K
    Arzneimittelforschung; 1985; 35(7):1086-9. PubMed ID: 2864937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.
    Fontanari D; Perulli L; Conte F; Tambato E; Toso V; Zanetti R
    Cephalalgia; 1983 Aug; 3 Suppl 1():189-91. PubMed ID: 6352048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of migraine with retard dihydroergotamine. Results of a multicenter study in 643 patients].
    Wörz R
    Fortschr Med; 1986 Nov; 104(43):838-42. PubMed ID: 3542767
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in migraine: treatment with dihydroergotamine-retard.
    Mastrosimone F; Iaccarino C
    Cephalalgia; 1983 Aug; 3 Suppl 1():168-70. PubMed ID: 6616599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
    Scott AK
    Clin Neuropharmacol; 1992 Aug; 15(4):289-96. PubMed ID: 1516074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.
    Pradalier A; Lantéri-Minet M; Géraud G; Allain H; Lucas C; Delgado A
    CNS Drugs; 2004; 18(15):1149-63. PubMed ID: 15581385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
    Centonze V; Attolini E; Santoiemma L; Brucoli C; Macinagrossa G; Campanozzi F; Albano O
    Cephalalgia; 1983 Aug; 3 Suppl 1():179-84. PubMed ID: 6616601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.